Because our goal was to identify “loss-of-function” cases, in which pathway redundancy is limited by lineage-specific gene expression, we have identified a potentially more tractable opportunity to target serine metabolism in luminal, not basal, breast cancer, in which serine biosynthesis is naturally limited by the hypermethylation of the PSAT1 gene. Here, PSAT1 is linked to breast cancer.